Clinical trials: Diabetes, Type II
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes
This trial is conducted globally. The aim of this trial is to assess the efficacy and safety of liraglutide in the paediatric population in order to potentially address the unmet need for treatment of children and adolescents…
- Trial name
- Ellipse™ (NCT01541215)
- Testing
- liraglutide, metformin
- Where
- 185 sites in United States, Australia and 34 more
- Volunteers
- 135 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification
Trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without oral antidiabetic treatment in need of…
- Trial name
- NCT02906917
- Testing
- Insulin degludec/insulin aspart, Insulin glargine, Insulin aspart
- Where
- 71 sites in United States, Algeria and 5 more
- Volunteers
- 532 people
- Sponsor
- Novo Nordisk A/S
Physical Inactivity, Type2 Diabetes Mellitus
Behavioral Change Communication for Physical Activity Among Females With Type2 Diabetes Mellitus
The marked discrepancy between predicted and actual prevalence of Type2 diabetes Mellitus (DM) with the actual cases rising earlier than expected, underscore the continuing relevance of tailored awareness and management…
- Trial name
- RCT (NCT00690326)
- Testing
- Behavioral change communication model(BCC) to promote physical activity, pamphlet-The printed pamphlet,'Physical activity:To control blood sugar/ Diabetes Mellitus'
- Where
- India
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Thiruvananthapuram Medical College
Diabetes Mellitus, Type 2
Feasibility Study on the Impact of Economic Incentives to Improve the Management of Type 2 Diabetes Mellitus
This feasibility study aims to compare the implementation process of three different interventions that use economic incentives to promote lifestyle behavioral changes in patients with type 2 diabetes mellitus, and to identify…
- Trial name
- REDEEM-Pilot (NCT02891382)
- Testing
- Diabetes education, Goal setting, Companion Support
- Where
- Peru
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Universidad Peruana Cayetano Heredia
Type 2 Diabetes
Diabetes Self-Management Models to Reduce Health Disparities
To evaluate the effectiveness of two different diabetes self-management approaches (Personal Digital Assistant-based intervention \& Chronic Disease Self-Management Program) to reduce health disparities in minority, rural…
- Trial name
- P20-P2 (NCT01221090)
- Testing
- PDA, CDSMP, PDA/CDSMP
- Where
- United States
- Volunteers
- 376 people, healthy volunteers welcome
- Sponsor
- Scott and White Hospital & Clinic
Diabetes Mellitus, Type 2
A Study of Insulin Lispro Mix in Type 2 Diabetic Asian Patients
The purpose is to evaluate the proportion of subjects achieving a Hemoglobin A1c (HbA1c) level below 6.5%, when lispro mix 50/50 is introduced in a stepwise manner from every day (QD) administration to type 2 diabetic patients…
- Trial name
- SIMPLE (NCT00971997)
- Testing
- Lispro Mix 50/50
- Where
- 14 sites in Japan
- Volunteers
- 135 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes
The purpose of this study is to test whether using extra doses of aspart insulin to correct blood sugars before meals improves the care of patients with type 2 diabetes in the hospital who are already receiving the standard of…
- Trial name
- NCT02408120
- Testing
- Insulin glargine, Insulin aspart, Supplemental insulin aspart
- Where
- 2 sites in United States
- Volunteers
- 226 people
- Sponsor
- Emory University
Diabetes Mellitus, Non-Insulin-Dependent, Hypertensive Disease
To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study
The investigators are conducting this research to study the effect of Liraglutide on blood pressure. Several studies have shown increased cardiovascular complications and deaths in diabetics with hypertension.
- Trial name
- NCT02299388
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Tulane University School of Medicine
Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor
Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
This retrospective observational target-trial emulation uses electronic health record data from the TriNetX US Collaborative Network to compare early treatment intensification strategies in adults with obesity, type 2 diabetes…
- Conditions
- Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor, Kidney Disease, Type 2 Diabetes
- Trial name
- GLP1-SGLT2-CKM (NCT07465926)
- Testing
- GLP-1 receptor agonist, SGLT2 inhibitor
- Volunteers
- 451,036 people
- Sponsor
- Chung Shan Medical University
Type 2 Diabetes Mellitus
Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants
To demonstrate the bioequivalence of a 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) tablet to that of 2.5-mg saxagliptin (Onglyza) and 500-mg metformin (Glucophage, marketed in Canada by Sanofi-Aventis)…
- Trial name
- NCT01068717
- Testing
- Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state), Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state), Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Study of LY3437943 in Participants With Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of…
- Trial name
- NCT04867785
- Testing
- LY3437943, Dulaglutide
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 281 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion
Background: Dedicated renal hemodynamic and renal function studies are lacking for DPP-4 inhibitors in patients with Type 2 diabetes; accordingly little is known regarding the mechanisms mediating the renal effects of DPP-4…
- Trial name
- INDORSE (NCT02406443)
- Testing
- Sitaglitpin
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- University Health Network, Toronto
Type 2 Diabetes Mellitus
A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)
A five-period crossover study to assess and compare the trough dipeptidyl peptidase IV (DPP-4) inhibition at 24-hours following the final morning dose for sitagliptin, saxagliptin and vildagliptin after 5 days of once daily…
- Trial name
- NCT01582308
- Testing
- Sitagliptin 100 mg, Saxagliptin 5 mg, Vildagliptin 50 mg
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetic Nephropathy
Nephropathy In Type 2 Diabetes and Cardio-renal Events
The NID-2 study, a multicentric study (21 centres enrolled), was planned in two phases: Phase 1(observational study, completed in September 2005): after the identification of a type-2 diabetic population with typical Diabetic…
- Trial name
- NID-2 (NCT00535925)
- Testing
- SoC therapy, irbesartan, ramipril
- Where
- Italy
- Volunteers
- 850 people
- Sponsor
- University of Campania Luigi Vanvitelli
Diabetes, Diabetes Mellitus, Type 2
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (IDeg) and liraglutide (Lira) in subjects with type 2 diabetes.
- Trial name
- DUAL™ I (NCT01336023)
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- 302 sites in United States, Australia and 18 more
- Volunteers
- 1,663 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), in adults with type 2 diabetes.
- Trial name
- NCT00286455
- Testing
- Alogliptin
- Where
- 67 sites in United States, Argentina and 16 more
- Volunteers
- 329 people
- Sponsor
- Takeda
Non-Insulin-dependent Diabetes Mellitus
Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects
A double-blind, randomized, placebo-controlled, multi-dose clinical study consisting of 2 phases; 1) an 8-week lead-in period during which patients followed a diet judged to be within the acceptable guidelines of the ADA, and 2)…
- Trial name
- NCT01582282
- Testing
- 3.4 g psyllium BID, 6.8g psyllium BID
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Procter and Gamble
Diabetes
Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM
Type 2 diabetes is a systemic metabolic disease with significant morbidity and mortality due to damaging blood vessels. Increased blood sugar level is a hallmark of diabetes and is an contributes to the development of many of its…
- Trial name
- NCT01107717
- Testing
- metformin\pioglitazone\exenatide, metformin, glyburide and glargine
- Where
- United States
- Volunteers
- 318 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Dyslipidemia
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
Primary Objective: To demonstrate the superiority of alirocumab in comparison with usual care in the reduction of non-high-density lipoprotein cholesterol (non-HDL-C) in participants with type 2 diabetes and mixed dyslipidemia at…
- Trial name
- NCT02642159
- Testing
- Alirocumab, Statins, Ezetimibe
- Where
- 119 sites in United States, Australia and 13 more
- Volunteers
- 413 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study of LY2405319 in Participants With Type 2 Diabetes
The main purpose of this study was to evaluate the safety and tolerability of LY2405319. It was given as a daily injection under the skin to participants with type 2 diabetes mellitus (T2DM) for 28 days.
- Trial name
- NCT01869959
- Testing
- LY2405319
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.